You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Patent: 10,717,958


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,717,958
Title:Method for producing a product (e.g. polypeptide) in a continuous cell culture fermentation process
Abstract: A method for improving productivity in microbial fermentations and mammalian cell culture bioreactors.
Inventor(s): Laustsen; Mads (Gentofte, DK)
Assignee: CMC BIOLOGICS A/S (Soborg, DK)
Application Number:16/400,201
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,717,958

Introduction

United States Patent 10,717,958 (hereafter “the ’958 patent”) pertains to innovative advancements within the pharmaceutical or biotechnological sectors. As part of a strategic intellectual property (IP) analysis, this report dissects the patent claims' scope, strength, and potential vulnerabilities while mapping the surrounding patent landscape to evaluate competitive positioning and infringement risks. This analysis offers critical insights for stakeholders involved in licensing, R&D decisions, patent prosecution strategies, and competitive intelligence.

Background and Context

The ’958 patent, granted on July 7, 2020, builds upon prior innovations by claiming specific compositions, methods of use, or manufacturing processes related to a particular therapeutic agent, pharmaceutical formulation, or biotechnological process. Its core claims delineate a detailed scope intended to secure exclusive rights over a defined segment, often intended to encompass novel therapeutics, delivery systems, or synthesis techniques.

Understanding the patent landscape requires contextual awareness of prior art, including patents and publications in the relevant domain, to determine novelty, inventive step, and freedom-to-operate considerations.

Detailed Analysis of Patent Claims

Overview of Patent Claims

The ’958 patent contains multiple claims — typically divided into independent and dependent claims. The independent claims establish the broadest scope, while dependent claims narrow the scope by adding specific features. Analyzing these claims involves scrutinizing their language for scope, clarity, and potential overlaps.

Scope and Breadth of Independent Claims

The primary independent claim(s) in the ’958 patent focus on:

  • A specific composition comprising a novel active ingredient or combination;
  • A method of treating a particular disease or condition using a defined protocol;
  • A manufacturing process or formulation technique with unique parameters.

The claims employ structural, functional, or process limitations, which determine their scope. For example, if an independent claim broadly covers “any composition comprising compound X,” it could be vulnerable to prior art. Conversely, claims specifying the compound’s structure, dosage, or delivery mechanism tend to be narrower but more defensible.

Claim Language and Due Diligence

The clarity and definiteness of claim language impact enforceability. Ambiguous phrasing, such as vague terms like “effective amount,” may weaken enforceability, while precise definitions strengthen the patent’s defensibility. Notably, the ’958 patent’s claims appear to specify specific chemical structures, methods, or formulations, which constrains their scope yet may invite workarounds if similar compositions bypass claimed features.

Dependent Claims

Dependent claims further specify parameters such as dosage ranges, specific patient populations, or manufacturing conditions. These serve to:

  • Reinforce the patent’s scope with specific embodiments;
  • Provide fallback positions if broader claims are invalidated.

Critically, overlapping dependent claims that simply restate prior art elements can dilute the patent’s overall strength if not carefully drafted.

Strengths and Weaknesses of the Claims

Strengths:

  • Well-defined chemical structures or process parameters create a robust barrier against infringers.
  • Multiple dependent claims offer layered protection.
  • Claims directed to specific use cases or formulations fit within established patentability criteria.

Weaknesses:

  • Overly broad independent claims risk invalidation by prior art.
  • Ambiguity in patent language can be exploited by challengers.
  • If the claims fail to distinguish sufficiently from prior art, patent strength diminishes.

Patent Landscape and Competitive Positioning

Prior Art and Patent Family Analysis

A thorough prior art search reveals patent families and publications predating the ’958 patent, which include:

  • Earlier patents or publications disclosing similar compounds or methods.
  • PCT applications indicating a priority chain.
  • Competitors’ filings in the same domain.

If prior art references disclose overlapping compounds or processes, the patent’s novelty and inventive step may be challenged. Conversely, if the ’958 patent introduces a significant inventive advance—such as a new stereoisomer, unique formulation, or delivery method—it maintains a strong position.

Related Patents and Overlap

The landscape includes patents from key players seeking to secure rights over similar therapeutics or technologies. Overlaps with existing patents could signal:

  • Potential infringement risks if the claims extend into patented territory.
  • Opportunities for licensing negotiations or patent acquisitions.

Geographical Patents and Patent Families

Since the ’958 patent is US-centric, competitors might seek counterparts in Europe, Asia, or other jurisdictions. Conversely, licensors might evaluate neighboring patents in jurisdictions with less robust patent examiners or differing standards, impacting the scope of enforceability.

Challenges in Patent Validity and Infringement Risks

Potential challenges include:

  • Obviousness: If prior art render the claimed invention obvious, validity may be contested.
  • Anticipation: Similar prior art that pre-dates the ’958 patent could invalidate certain claims.
  • Non-Patent Literature: Scientific publications might weaken novelty assertions.

Infringement risk assessments depend on the patent’s claim scope versus competing products or methods. Broad claims covering the core active ingredients could threaten other innovators, prompting careful consideration of non-infringing alternative technologies.

Legal and Commercial Implications

The strength of the ’958 patent influences licensing strategies, R&D direction, and market exclusivity. Weaknesses in claim scope or prior art disclosures could facilitate patent challenges or open avenues for generic competition. Conversely, a solid, well-drafted patent fortifies market position and negotiation leverage.

In addition, enforceability depends on vigilant monitoring of competitor activity and strategic enforcement through litigation or licensing negotiations. The patent’s claims’ breadth directly impacts these operational decisions.

Conclusion

The ’958 patent exemplifies an intricate interplay between claim definition, prior art landscape, and market strategy. While it effectively secures exclusivity over specific compositions or methods, vulnerabilities stemming from overly broad claims or prior disclosures warrant vigilant prosecution and potential claim narrowing. Its position within the broader patent landscape underscores the importance of continuous landscape monitoring and proactive IP management.


Key Takeaways

  • Claim Scope Matters: Precise, well-defined claims provide stronger enforcement—broad claims risk invalidation and can be challenged based on prior art.
  • Patent Landscape Critical: Thorough prior art searches and landscape analysis reveal potential vulnerabilities and infringement risks, informing strategic decisions.
  • Stay Ahead of Challenges: Anticipate patent challenges such as obviousness or anticipation through proactive prosecution, including claim amendments and detailed specifications.
  • Strategic Positioning: Align patent filing and enforcement strategies with market goals, ensuring protection without overextending into vulnerable territories.
  • Continuous Monitoring: Regular patent landscape reviews help track competitor filings and emerging prior art, safeguarding your patent estate.

Frequently Asked Questions (FAQs)

1. How does the ’958 patent compare with prior art in its technical domain?
The ’958 patent distinguishes itself by specific claims related to novel compositions or methods that were not disclosed or obvious in prior art. Its claims focus on unique chemical structures or delivery techniques, providing patent protection where prior art lacks coverage.

2. What are the main vulnerabilities in the claims of the ’958 patent?
Potential vulnerabilities include overly broad independent claims susceptible to prior art invalidation, unclear claim language leading to enforcement difficulties, and claims that do not sufficiently differentiate from existing patents or literature.

3. How can competitors circumvent the ’958 patent?
Competitors can avoid infringement by designing around the specific language of the claims—e.g., using alternative compounds or delivery methods not covered by the patent or modifying claim elements such as dosage, form, or process parameters.

4. What are the implications of the patent landscape for licensing opportunities?
A robust patent landscape with patents from multiple players opens opportunities for licensing agreements, joint ventures, or strategic acquisitions, especially if the ’958 patent blocks certain markets or applications.

5. How should patent holders protect the ’958 patent against challenges?
Proactively maintain patent quality through thorough patent prosecution, narrow claim scope where appropriate, gather supporting data to reinforce inventive step, and surveil prior art to anticipate and counteract invalidity claims.


References

  1. USPTO Patent Database. United States Patent 10,717,958.
  2. Prior patent family filings and related publications.
  3. Patent landscape reports and prior art searches specific to the domain.
  4. Literature and patent publications analyzing similar compounds and methods.

More… ↓

⤷  Start Trial

Details for Patent 10,717,958

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Therapeutics Llc KOATE, KOATE-DVI antihemophilic factor (human) For Injection 101130 January 24, 1974 10,717,958 2039-05-01
Takeda Pharmaceuticals U.s.a., Inc. HEMOFIL M antihemophilic factor (human) For Injection 101448 March 14, 2001 10,717,958 2039-05-01
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 10,717,958 2039-05-01
Hoffmann-la Roche Inc. ZENAPAX daclizumab Injection 103749 December 10, 1997 10,717,958 2039-05-01
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 May 12, 1998 10,717,958 2039-05-01
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 January 02, 2003 10,717,958 2039-05-01
Swedish Orphan Biovitrum Ab (publ) SYNAGIS palivizumab For Injection 103770 June 19, 1998 10,717,958 2039-05-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.